High platelet count in platelet-rich plasma reduces measured platelet inhibition by abciximab but not tirofiban nor eptifibatide glycoprotein IIb/IIIa receptor antagonists

Journal of Thrombosis and Thrombolysis

Volumn 9, Issue 2, 2000, Pages 149-155

  Kereiakes, Dean J ^a   Broderick, Thomas M ^b   Roth, Eli M ^b   Whang, David ^a   Mueller, Michele ^a   Lacock, Pam ^c   Anderson, Linda C ^a   Howard, Wendy ^a   Blanck, Chris ^a   Schneider, John ^a   Abbottsmith, Charles A ^c  

^a The Carl & Edyth Lindner Center for Research & Education   (United States)

^b Ohio Heart and Vascular Center   (United States)

^c HEALTH ALLIANCE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; TIROFIBAN;

ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

EID: 0033952861     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018718914065     Document Type: Article

References (28)

1. tenCate JW. Platelet function tests. Clin Hematol 1972;1: 283-294.
2. Tcheng JE, Ellis SG, George BS, et al. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 73 in high risk coronary angioplasty. Circulation 1994;90:1757-1764.
3. Kereiakes DJ, Kleiman NS, Ambrose J, et al. A randomized, double-blind, placebo-controlled dose ranging study of MK-383 platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol 1996; 27: 536-542.
4. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994;330: 956-961.
5. The EPILOG investigators Platelet glycoprotein IIb/IIIa receptor blockade in low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997;336: 1689-1696.
6. Tcheng JE, Harrington RA, Kottke-Marschant K, et al. Multicenter randomized double blind placebo controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrilin in elective coronary intervention. Circulation 1995;91: 2151-2157.
7. The Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998;338:1498-1505.
8. Gold HK, Gimple L, Yasuda T, et al. Pharmacodynamic study of F(ab′)2 fragments of murine monoclonal antibody 7E3 directed against human platelet glycoprotein IIb/IIIa in patients with unstable angina pectoris. J Clin Invest 1990; 86:651-659.
9. Coller BS, Scudder LE, Beer J, et al. Monoclonal antibodies to platelet GP IIb/IIIa as antithrombotic agents. Ann N Y Acad Sci 1991;614:193-213.
10. Cannon CP, McCabe CH, Borzak S, et al. for the TIMI 12 Investigators. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome: Results of the TIMI 12 trial. Circulation. 1998;97:340-349.
11. Levine PH. An acute effect of cigarette smoking on platelet function. Circulation 1973;48:619-623.
12. Levine PH. The effect of thrombocytopenia on determination of platelet aggregation. Am J Clin Pathol 1976;65: 79-82.
13. Trip MD, Gats VM, van Capelle FJL, Vreeken J. Platelet hyper-reactivity and prognosis in survivors of myorcadial infarction. N Engl J Med 1990;322:1549-1554.
14. Coller BS. Platelet aggregation by ADP, collagen and ristocetin: A critical review of methodology and analysis. In Schmidt RM, ed. CRC Handbook Series in Clinical Laboratory Science. Boca Raton, FL: 1979:381.
15. Mascelli MA, Lance ET, Damaraju L, Wagner CL, Weisman HF, Jordan RE. Pharmacodynamic profile of short term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998;97:1680-1688.
16. Kereiakes DJ, Broderick TM, Roth EM, et al. A randomized comparative study of the time course, magnitude and consistency of platelet inhibition by abciximab, tirofiban or eptifibatide in patients with unstable angina pectoris undergoing percutaneous coronary intervention. Am J Cardiol 1999;84:391-395.
17. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT -II. Lancet 1997;349:1422-1428.
18. Coller BS, Springer KT, Scudder LE, Kutok JL, Ceruso M, Prestwich GD. Substituting isoserine for serine in the thrombin receptor activation peptide SFLLRN confers resistance to aminopeptidase M-induced cleavage and inactivation. J Biol Chem 1993;268:20741-20743.
19. Mascelli MA, Worley S, Veriabo NJ, et al. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti GP IIb/IIIa therapy. Circulation 1997;96:3860-3866.
20. Smith, JW, Steinhubl SR, Lincoff AM, Coleman J, Li T, Hillman RS, Coller BS. The rapid platelet function assay (RPFA): An automated and quantitative cartridge-based method. Circulation 1999;99:620-625.
21. Simoons ML, de Boer MJ, van den Brand MJ, et al. for the European Cooperative Study Group. Randomized trial of a GP IIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation 1994;89:596-603.
22. Wencel-Drake J, Plow E, Zimmerman T, Painter R, Ginsberg M. Immunofluorescent localization of adhesive glycoprotein in resting and thrombin-stimulated platelet. Am J Pathol 1984;115:156-164.
23. Kleiman NS, Raizner AE, Jordan R, et al. Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GP IIb/IIIa receptors. J Am Coll Cardiol 1995;26:1665-1671.
24. Schwartz KA, Schwartz DE, Gregoire EJ, Davis JM. Abciximab platelet inhibition as monitored by the cationic propyl gallate platelet aggregometry assay (CPG-PAA) is inversely related to platelet concentration. Blood 1998;92 (Suppl.).
25. Valles J, Santos MT, Aznar J, et al. Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: The effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocytes on platelet reactivity. Circulation 1998;97:350-355.
26. Mascelli MA, Worley S, Veriabo NJ, et al. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy. Circulation 1997; 96:3860-3866.
27. 2+ on GP IIb/IIIa interactions with integrilin. Circulation 1997;96: 1488-1494.
28. Storey RF, Wilcox RG, Heptinstall S. Differential effects of glycoprotein IIb/IIIa antagonists on platelet microaggregate and macroaggregate formation and effect of anticoagulant on antagonist potency. Implications for assay methodology and comparison of different antagonists. Circulation 1998;98:1616-1621.